PharmacyCodes



Rifater en es it fr

Rifater Brand names, Rifater Analogs

Rifater Brand Names Mixture

  • Rifater (Isoniazid + Pyrazinaamide + Rifampin)
  • Rifamate (Rifampin + Isoniazid)

Rifater Chemical_Formula

C43H58N4O12

Rifater RX_link

http://www.rxlist.com/cgi/generic2/rifampin.htm

Rifater fda sheet

Rifater FDA

Rifater msds (material safety sheet)

Rifater MSDS

Rifater Synthesis Reference

No information avaliable

Rifater Molecular Weight

822.94 g/mol

Rifater Melting Point

183 oC

Rifater H2O Solubility

1.4 mg/mL

Rifater State

Solid

Rifater LogP

3.719

Rifater Dosage Forms

Capsule

Rifater Indication

For the treatment of Tuberculosis and Tuberculosis-related mycobacterial infections.

Rifater Pharmacology

Rifampin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. Because of rapid emergence of resistant bacteria, use is restricted to treatment of mycobacterial infections and a few other indications. Rifampin is well absorbed when taken orally and is distributed widely in body tissues and fluids, including the CSF. It is metabolized in the liver and eliminated in bile and, to a much lesser extent, in urine, but dose adjustments are unnecessary with renal insufficiency.

Rifater Absorption

Well absorbed from gastrointestinal tract.

Rifater side effects and Toxicity

LD50=1570 mg/kg (rat), chronic exposure may cause nausea and vomiting and unconsciousness

Rifater Patient Information

The patient should be told that rifampin may produce a reddish coloration of the urine, sweat, sputum, and tears, and the patient should be forewarned of this. Soft contact lenses may be permanently stained. The patients should be advised that the reliability of oral or other systemic hormonal contraceptives may be affected; consideration should be given to using alternative contraceptive measures. Patients should be instructed to take rifampin either 1 hour before or 2 hours after a meal with a full glass of water. Patients should be instructed to notify their physicians promptly if they experience any of the following: fever, loss of appetite, malaise, nausea and vomiting, darkened urine, yellowish discoloration of the skin and eyes, and pain or swelling of the joints. Compliance with the full course of therapy must be emphasized, and the importance of not missing any doses must be stressed.

Rifater Organisms Affected

Mycobacteria and a variety of other gram negative and gram postivie bacteria